PT3166933T - Compostos de epoxicetona para inibição de enzimas - Google Patents
Compostos de epoxicetona para inibição de enzimasInfo
- Publication number
- PT3166933T PT3166933T PT15821964T PT15821964T PT3166933T PT 3166933 T PT3166933 T PT 3166933T PT 15821964 T PT15821964 T PT 15821964T PT 15821964 T PT15821964 T PT 15821964T PT 3166933 T PT3166933 T PT 3166933T
- Authority
- PT
- Portugal
- Prior art keywords
- enzyme inhibition
- epoxyketone compounds
- epoxyketone
- compounds
- inhibition
- Prior art date
Links
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical class O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 title 1
- 102000004190 Enzymes Human genes 0.000 title 1
- 108090000790 Enzymes Proteins 0.000 title 1
- 230000005764 inhibitory process Effects 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06078—Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
- C07K5/0202—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-X-X-C(=0)-, X being an optionally substituted carbon atom or a heteroatom, e.g. beta-amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0802—Tripeptides with the first amino acid being neutral
- C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
- C07K5/0806—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0821—Tripeptides with the first amino acid being heterocyclic, e.g. His, Pro, Trp
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Tropical Medicine & Parasitology (AREA)
- Biomedical Technology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- AIDS & HIV (AREA)
- Hospice & Palliative Care (AREA)
- Dermatology (AREA)
- Pain & Pain Management (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462024024P | 2014-07-14 | 2014-07-14 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PT3166933T true PT3166933T (pt) | 2018-12-06 |
Family
ID=55079165
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT15821964T PT3166933T (pt) | 2014-07-14 | 2015-07-14 | Compostos de epoxicetona para inibição de enzimas |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US10640533B2 (enExample) |
| EP (1) | EP3166933B1 (enExample) |
| JP (1) | JP6608442B2 (enExample) |
| KR (2) | KR102360356B1 (enExample) |
| CN (1) | CN105960399B (enExample) |
| DK (1) | DK3166933T3 (enExample) |
| ES (1) | ES2704056T3 (enExample) |
| PT (1) | PT3166933T (enExample) |
| TR (1) | TR201816372T4 (enExample) |
| WO (1) | WO2016011088A2 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016011088A2 (en) | 2014-07-14 | 2016-01-21 | Centrax International, Inc. | Epoxyketone compounds for enzyme inhibition |
| US20240092831A1 (en) * | 2019-10-11 | 2024-03-21 | Mayo Foundation For Medical Education And Research | Proteasome Inhibitors |
| TWI869142B (zh) * | 2022-12-27 | 2025-01-01 | 大陸商上海美悦生物科技發展有限公司 | 三肽環氧酮化合物、藥物組合物及其製備方法和用途 |
| WO2026041079A1 (zh) * | 2024-08-23 | 2026-02-26 | 江苏正大清江制药有限公司 | 肽环氧酮类化合物及其制备方法和应用 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE494298T1 (de) * | 2004-04-15 | 2011-01-15 | Proteolix Inc | Verbindungen zur proteasomenzymhemmung |
| AU2005243140A1 (en) * | 2004-05-10 | 2005-11-24 | Proteolix, Inc. | Synthesis of amino acid keto-epoxides |
| EP2261236B1 (en) * | 2004-12-07 | 2015-07-15 | Onyx Therapeutics, Inc. | Composition for proteasome inhibition |
| EP2623113B1 (en) * | 2005-11-09 | 2017-05-31 | Onyx Therapeutics, Inc. | Compound for enzyme inhibition |
| WO2008140782A2 (en) | 2007-05-10 | 2008-11-20 | Proteolix, Inc. | Compounds for enzyme inhibition |
| JP5675629B2 (ja) | 2008-10-21 | 2015-02-25 | オニキス セラピューティクス， インク．Ｏｎｙｘ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． | ペプチドエポキシケトンを用いた併用療法 |
| CA2795559A1 (en) * | 2010-04-07 | 2011-11-03 | Onyx Therapeutics, Inc. | Crystalline peptide epoxyketone immunoproteasome inhibitor |
| EP4706663A3 (en) | 2011-08-30 | 2026-05-20 | Trustees Of Tufts College | FAP-ACTIVATED PROTEASOME INHIBITORS USED TO TREAT SOLID TUMORS |
| WO2014015157A2 (en) | 2012-07-19 | 2014-01-23 | Philadelphia Health & Education Corporation | Novel sigma receptor ligands and methods of modulating cellular protein homeostasis using same |
| WO2014018807A1 (en) * | 2012-07-26 | 2014-01-30 | Centrax International, Inc. | Peptide epoxyketone compounds |
| CA2881999A1 (en) * | 2012-08-14 | 2014-02-20 | Abdelmalik Slassi | Fluorinated epoxyketone-based compounds and uses thereof as proteasome inhibitors |
| WO2014029022A1 (en) * | 2012-08-21 | 2014-02-27 | Abdelmalik Slassi | Fluorinated epoxyketone-based tetrapeptide compounds and uses thereof as proteasome inhibitors |
| WO2016011088A2 (en) | 2014-07-14 | 2016-01-21 | Centrax International, Inc. | Epoxyketone compounds for enzyme inhibition |
-
2015
- 2015-07-14 WO PCT/US2015/040459 patent/WO2016011088A2/en not_active Ceased
- 2015-07-14 KR KR1020177004070A patent/KR102360356B1/ko active Active
- 2015-07-14 CN CN201580002532.1A patent/CN105960399B/zh active Active
- 2015-07-14 JP JP2017523185A patent/JP6608442B2/ja active Active
- 2015-07-14 EP EP15821964.2A patent/EP3166933B1/en active Active
- 2015-07-14 ES ES15821964T patent/ES2704056T3/es active Active
- 2015-07-14 PT PT15821964T patent/PT3166933T/pt unknown
- 2015-07-14 TR TR2018/16372T patent/TR201816372T4/tr unknown
- 2015-07-14 DK DK15821964.2T patent/DK3166933T3/en active
- 2015-07-14 KR KR1020217022768A patent/KR102462240B1/ko active Active
- 2015-07-14 US US15/325,998 patent/US10640533B2/en active Active
-
2019
- 2019-10-28 US US16/665,010 patent/US10787482B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| DK3166933T3 (en) | 2018-11-26 |
| EP3166933A4 (en) | 2017-07-19 |
| KR102462240B1 (ko) | 2022-11-03 |
| KR20170041747A (ko) | 2017-04-17 |
| US10640533B2 (en) | 2020-05-05 |
| JP2017522383A (ja) | 2017-08-10 |
| EP3166933B1 (en) | 2018-08-01 |
| CN105960399B (zh) | 2018-09-25 |
| US20200087343A1 (en) | 2020-03-19 |
| KR102360356B1 (ko) | 2022-02-08 |
| TR201816372T4 (tr) | 2018-11-21 |
| US20170158734A1 (en) | 2017-06-08 |
| CN105960399A (zh) | 2016-09-21 |
| JP6608442B2 (ja) | 2019-11-20 |
| US10787482B2 (en) | 2020-09-29 |
| WO2016011088A3 (en) | 2016-08-11 |
| KR20210093378A (ko) | 2021-07-27 |
| ES2704056T3 (es) | 2019-03-14 |
| EP3166933A2 (en) | 2017-05-17 |
| WO2016011088A2 (en) | 2016-01-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL287113A (en) | smyd inhibitors | |
| GB201421083D0 (en) | Enzyme inhibitors | |
| IL246785A0 (en) | Benzimidazole-2-amines as midh1 inhibitors | |
| GB201421088D0 (en) | New enzyme inhibitors | |
| EP3116503A4 (en) | Hptp-beta inhibitors | |
| EP3099695A4 (en) | Compounds | |
| GB201416446D0 (en) | New enzyme inhibitor compounds | |
| IL248895A0 (en) | Phosphatidylinositol 3-kinase inhibitors | |
| SG11201610904UA (en) | Syk inhibitors | |
| EP3224246A4 (en) | 4-oxoquinoline compounds | |
| EP3099694A4 (en) | Compounds | |
| EP3172208A4 (en) | Compounds | |
| EP3142667A4 (en) | Methods for inhibiting necroptosis | |
| GB201421085D0 (en) | New enzyme inhibitors | |
| GB201403536D0 (en) | Inhibitor compounds | |
| EP3110792A4 (en) | Aminocarbonylcarbamate compounds | |
| AP2017009778A0 (en) | Azetidinyloxyphenylpyrrolidine compounds | |
| EP3149010A4 (en) | Monoaminosilane compounds | |
| GB201415429D0 (en) | Corrosion inhibition | |
| EP3227470A4 (en) | Corrosion inhibition | |
| EP3190891A4 (en) | Substituted cyclohexylamine compounds | |
| EP3166933A4 (en) | Epoxyketone compounds for enzyme inhibition | |
| EP3213751A4 (en) | Phacosclerosis inhibitor | |
| GB201415614D0 (en) | Corosion Inhibition | |
| GB201401005D0 (en) | Inhibitor |